Comparison of effects of pioglitazone and glimepiride on plasma soluble RAGE and RAGE expression in peripheral mononuclear cells in type 2 diabetes: Randomized controlled trial (PioRAGE)

Atherosclerosis

Volumn 234, Issue 2, 2014, Pages 329-334

  Koyama, Hidenori ^a   Tanaka, Shinji ^a   Monden, Masayo ^a   Shoji, Takuhito ^a   Morioka, Tomoaki ^a   Fukumoto, Shinya ^a   Mori, Katsuhito ^a   Emoto, Masanori ^a   Shoji, Tetsuo ^a   Fukui, Mitsuru ^a   Fujii, Hisako ^b   Nishizawa, Yoshiki ^a   Inaba, Masaaki ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA CITY UNIVERSITY HOSPITAL   (Japan)

Author keywords

Randomized clinical trial; Receptor for advanced glycation end products (RAGE); Soluble RAGE; Thiazolidinedione

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ALANINE AMINOTRANSFERASE; ASPARTIC ACID; GAMMA GLUTAMYLTRANSFERASE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOREACTIVE INSULIN; METFORMIN; NATEGLINIDE; PIOGLITAZONE; URATE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; IMMUNOGLOBULIN RECEPTOR; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC PATIENT; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HUMAN CELL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; URIC ACID BLOOD LEVEL; WEIGHT GAIN; BLOOD; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; JAPAN; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; JAPAN; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; RECEPTORS, IMMUNOLOGIC; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84900849425     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.03.025     Document Type: Article

References (36)

1. Brownlee M., Cerami A., Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. NEngl J Med 1988, 318:1315-1321.
2. Baynes J.W., Thorpe S.R. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999, 48:1-9.
3. Miyata T., Kurokawa K., Van Ypersele De Strihou C. Advanced glycation and lipoxidation end products: role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism. JAm Soc Nephrol 2000, 11:1744-1752.
4. Yan S.F., Ramasamy R., Naka Y., Schmidt A.M. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res 2003, 93:1159-1169.
5. Nawroth P., Bierhaus A., Marrero M., Yamamoto H., Stern D.M. Atherosclerosis and restenosis: is there a role for RAGE?. Curr Diab Rep 2005, 5:11-16.
6. Park L., Raman K.G., Lee K.J., Lu Y., Ferran L.J., Chow W.S., et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998, 4:1025-1031.
7. Cipollone F., Iezzi A., Fazia M., Zucchelli M., Pini B., Cuccurullo C., et al. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 2003, 108:1070-1077.
8. Pettersson-Fernholm K., Forsblom C., Hudson B.I., Perola M., Grant P.J., Groop P.H. The functional -374 T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in type 1 diabetic patients. Diabetes 2003, 52:891-894.
9. Soro-Paavonen A., Watson A.M., Li J., Paavonen K., Koitka A., Calkin A.C., et al. Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 2008, 57:2461-2469.
10. Raucci A., Cugusi S., Antonelli A., Barabino S.M., Monti L., Bierhaus A., et al. Asoluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 2008, 22:3716-3727.
11. Zhang L., Bukulin M., Kojro E., Roth A., Metz V.V., Fahrenholz F., et al. Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. JBiol Chem 2008, 283:35507-35516.
12. Yonekura H., Yamamoto Y., Sakurai S., Petrova R.G., Abedin M.J., Li H., et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003, 370:1097-1109.
13. Koyama H., Shoji T., Yokoyama H., Motoyama K., Mori K., Fukumoto S., et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2005, 25:2587-2593.
14. Koyama H., Shoji T., Fukumoto S., Shinohara K., Emoto M., Mori K., et al. Low circulating endogenous secretory receptor for AGEs predicts cardiovascular mortality in patients with end-stage renal disease. Arterioscler Thromb Vasc Biol 2007, 27:147-153.
15. Selvin E., Halushka M.K., Rawlings A.M., Hoogeveen R.C., Ballantyne C.M., Coresh J., et al. sRAGE and risk of diabetes, cardiovascular disease, and death. Diabetes 2013, 62:2116-2121.
16. Staels B., Fruchart J.C. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 2005, 54:2460-2470.
17. Mazzone T., Meyer P.M., Feinstein S.B., Davidson M.H., Kondos G.T., D'Agostino R.B., et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAm Med Assoc 2006, 296:2572-2581.
18. Nissen S.E., Nicholls S.J., Wolski K., Nesto R., Kupfer S., Perez A., et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAm Med Assoc 2008, 299:1561-1573.
19. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279-1289.
20. Lincoff A.M., Wolski K., Nicholls S.J., Nissen S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAm Med Assoc 2007, 298:1180-1188.
21. Yki-Jarvinen H. The PROactive study: some answers, many questions. Lancet 2005, 366:1241-1242.
22. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
23. Seino Y., Nanjo K., Tajima N., Kadowaki T., Kashiwagi A., Araki E., et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. JDiabetes Invest 2010, 1:212-228.
24. Emoto M., Nishizawa Y., Maekawa K., Hiura Y., Kanda H., Kawagishi T., et al. Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care 1999, 22:818-822.
25. Sakurai S., Yamamoto Y., Tamei H., Matsuki H., Obata K., Hui L., et al. Development of an ELISA for esRAGE and its application to type 1 diabetic patients. Diabetes Res Clin Pract 2006, 73:158-165.
26. Hou F.F., Ren H., Owen W.F., Guo Z.J., Chen P.Y., Schmidt A.M., et al. Enhanced expression of receptor for advanced glycation end products in chronic kidney disease. JAm Soc Nephrol 2004, 15:1889-1896.
27. Shoji T., Koyama H., Morioka T., Tanaka S., Kizu A., Motoyama K., et al. Receptor for advanced glycation end products is involved in impaired angiogenic response in diabetes. Diabetes 2006, 55:2245-2255.
28. Tan K.C., Chow W.S., Tso A.W., Xu A., Tse H.F., Hoo R.L., et al. Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes. Diabetologia 2007, 50:1819-1825.
29. Blind E., Dunder K., de Graeff P.A., Abadie E. Rosiglitazone: a European regulatory perspective. Diabetologia 2011, 54:213-218.
30. Home P.D., Pocock S.J., Beck-Nielsen H., Curtis P.S., Gomis R., Hanefeld M., et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009, 373:2125-2135.
31. Bhatt D.L., Chew D.P., Grines C., Mukherjee D., Leesar M., Gilchrist I.C., et al. Peroxisome proliferator-activated receptor gamma agonists for the prevention of adverse events following percutaneous coronary revascularization-results of the PPAR study. Am Heart J 2007, 154:137-143.
32. Ouslimani N., Mahrouf M., Peynet J., Bonnefont-Rousselot D., Cosson C., Legrand A., et al. Metformin reduces endothelial cell expression of both the receptor for advanced glycation end products and lectin-like oxidized receptor 1. Metabolism 2007, 56:308-313.
33. Marx N., Walcher D., Ivanova N., Rautzenberg K., Jung A., Friedl R., et al. Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products. Diabetes 2004, 53:2662-2668.
34. Monden M., Koyama H., Otsuka Y., Morioka T., Mori K., Shoji T., et al. Receptor for advanced glycation end products regulates adipocyte hypertrophy and insulin sensitivity in mice: involvement of Toll-like receptor 2. Diabetes 2013, 62:478-489.
35. Forbes J.M., Thorpe S.R., Thallas-Bonke V., Pete J., Thomas M.C., Deemer E.R., et al. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. JAm Soc Nephrol 2005, 16:2363-2372.
36. Yamamoto Y., Miura J., Sakurai S., Watanabe T., Yonekura H., Tamei H., et al. Assaying soluble forms of receptor for advanced glycation end products. Arterioscler Thromb Vasc Biol 2007, 27:e33-e34.